ENX-104 clinical trials
Also written ENX-104.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2025
How each study uses ENX-104 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ENX-104
- 3
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Engrail Therapeutics INC (3)
Studies
Open first, then newest update. How each study uses ENX-104 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of ENX-104 in Healthy ParticipantsCompletedPhase 1Engrail Therapeutics INCNCT07472361Written as ENX-104
- ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD)CompletedPhase 1Engrail Therapeutics INCNCT07253324Written as ENX-104
- A PET Study of ENX-104 in Healthy VolunteersCompletedPhase 1Engrail Therapeutics INCNCT07253272Written as ENX-104